EMS Conference Raises Concerns And Awareness

Medical Directors discuss problems and solutions facing EMS workers

View Comments (
)
|
Email
|
Print

    NEWSLETTERS

    The decisions made at the "EMS State of Science" conference in Dallas this weekend will effect 80 million people worldwide.

    Dr Jon Jui, a Medical Director from Portland said it allows them to discuss the problems and solutions EMS workers face on a daily basis,

    "It allows us to share information discuss things that really work and discuss things that didn't work," said Jui.

    Medical directors will also take a first look at some of the new technology that could one day be used in ambulances Worldwide.

    EMS Conference Raises Concerns And Awareness

    [DFW] EMS Conference Raises Concerns And Awareness
    Medical Directors from around the World came together to discuss new technology

    Corey Slovis, a Medical Director from Nashville, said their job is to separate the good ones from the bad ones.

    "One of our most important jobs is separating the science from the hype, and that is, there are so many devices that cost so much money, what's worth it?" said Slovis.

    Devices like a newer version of the CPR machine which could reduce the risk of patients who don't survive cardiac arrest and keep patients alive longer on the way to the hospital.

    But it's the shortage of medicine that is a hot topic.

    Craig Manifold, a Medical Director in San Antonio, warned the shortage of medications is on a national crisis level.  If EMS workers do not have the medicine they need on the ambulance, they are forced to share with other EMS crews or used expired medication.

    "I think it is a National crisis because we are at a point in time where drugs are expiring... may or may not have drugs..and that's a critical problem," said A.J. Heightman, from the Emergency Medical Services Journal.

    Medical directors said there are many reasons why the drugs are in such low supply.

    Some speculations include that the drug companies stopped making the medicines - mostly generics with low profit-margins -- in a dispute over new federal regulations.

    The justice department launched an investigation several weeks ago into whether some companies are creating artificial shortages and simply price gouging.